Welcome to our dedicated page for Ping An Biomedical SEC filings (Ticker: PASW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Ping An Biomedical Co., Ltd. (NASDAQ: PASW) provides access to the company’s U.S. regulatory disclosures as they become available through the EDGAR system. Ping An Biomedical describes itself as a one-stop SCM service provider in the apparel industry and also as a company focused on healthcare and biomedical technology, and its filings are the primary source for detailed information on these activities.
Through this page, investors can review key filing types when they are submitted, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss business segments, risk factors, and management’s analysis of operations. Current reports on Form 8-K, when filed, can disclose material events such as strategic investment memoranda, share purchase agreements, or notices related to listing standards.
Ping An Biomedical has publicly reported receiving a Nasdaq minimum bid price deficiency letter, and any related developments may also appear in its SEC filings. In addition, ownership and insider activity, when reported on Form 3, 4, or 5, can be accessed from this page to understand changes in shareholdings of directors, officers, or significant holders.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents in plain language. Real-time updates from EDGAR, combined with AI-generated highlights of sections such as business descriptions, risk discussions, and capital market disclosures, help readers navigate Ping An Biomedical’s regulatory record more efficiently.
Ping An Biomedical Co., Ltd. CEO Liu Pijun has filed an initial statement of beneficial ownership. The filing shows that 12,250,000 Class A Ordinary Shares are held indirectly through INSPIRETECH LTD, reflecting a substantial position associated with the chief executive but does not report any recent share purchases or sales.
Ping An Biomedical Co., Ltd. filed a Form 3 identifying Liu Xianzhi (XZL) as a director and reporting person. The filing does not list any insider purchase, sale, or other equity transaction, and shows no derivative positions or holding entries in this report.
Ping An Biomedical Co., Ltd. CFO Yang Hongli filed an initial Form 3 as an officer of the company. The filing lists no reportable transactions, and the transaction summary shows zero buys, sells, exercises, gifts, tax withholdings, or restructurings, with derivative positions also not reported.
Ping An Biomedical Co., Ltd. reported that shareholders approved all five resolutions at the 2026 annual general meeting in Hong Kong. The vote authorizes a major overhaul of the company’s share capital structure, including the creation of high-vote Class B shares and a future share consolidation.
Authorised share capital will become US$312,500, divided into 4,900,000,000 Class A ordinary shares and 100,000,000 Class B ordinary shares, each with a par value of US$0.0000625. Shareholders also adopted a second amended and restated memorandum and articles of association tied to these capital changes.
The meeting further approved a targeted transaction with major shareholder INSPIRETECH LTD, allowing the company to repurchase 12,250,000 Class A shares from INSPIRETECH in exchange for issuing 12,250,000 Class B shares, leaving INSPIRETECH’s total share count unchanged but shifting part of its holding into high-vote stock. A large-scale share consolidation may be implemented within one year at the board’s discretion, with the company’s governing documents to be amended to reflect the consolidation once effected.
Ping An Biomedical has called its Annual General Meeting for March 18, 2026 in Hong Kong. Shareholders will vote on major capital and governance changes.
Key items include amending authorised share capital to US$312,500 divided into 4,900,000,000 Class A ordinary shares and 100,000,000 Class B ordinary shares, both with a par value of US$0.0000625. The company seeks to adopt a Second Amended and Restated Memorandum and Articles of Association, replacing the existing governing documents.
Shareholders are also asked to authorise a Share Repurchase and Issue in which the board may repurchase 12,250,000 Class A shares from INSPIRETECH LTD, funded by issuing 12,250,000 new Class B shares to INSPIRETECH. Additional proposals cover a share consolidation and related conforming amendments. Holders of ordinary shares at the March 3, 2026 record date may vote in person or by proxy, and the board unanimously recommends voting in favour of all proposals.
Ping An Biomedical Co., Ltd. entered into securities purchase agreements with accredited investors for a private placement of 100,000,000 ordinary shares at $0.04 per share, for total gross proceeds of $4,000,000. The transaction is expected to close within three business days of February 9, 2026, subject to customary conditions.
The shares are being sold in an unregistered offering relying on Section 4(a)(2), Regulation D, and Regulation S exemptions. Investors must be accredited or non‑U.S. persons, and the ordinary shares will carry transfer restrictions and restrictive legends because they are not registered under the U.S. Securities Act.
Ping An Biomedical Co., Ltd. files its annual report on Form 20-F for the year ended September 30, 2025, covering its apparel-focused operations in China conducted through PRC subsidiary New Brand. As of September 30, 2025, 20,500,000 ordinary shares were outstanding.
The company highlights extensive risks tied to operating in mainland China and Hong Kong, including rapid regulatory changes, data and cybersecurity oversight, capital controls, and potential trading prohibitions under the HFCA Act if PCAOB access to auditors is restricted. It notes reliance on PRC and CSRC approvals for overseas listings, and uncertainty around evolving CAC rules.
Business risks include a limited operating history, net losses, going concern and liquidity pressures, heavy dependence on a few major customers, supplier and quality-control risks, rising raw material and labor costs, and seasonality. The report also discloses material weaknesses in internal control over financial reporting, including inadequate segregation of duties and lack of independent directors and an audit committee.